



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P O Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

## NOTICE OF ALLOWANCE AND FEE(S) DUE

27195 7590 09/25/2008

AMIN, TUROCY & CALVIN, LLP  
24TH FLOOR, NATIONAL CITY CENTER  
1900 EAST NINTH STREET  
CLEVELAND, OH 44114

EXAMINER

STARKS, WILBERT L

ART UNIT

PAPER NUMBER

2129

DATE MAILED: 09/25/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/430,767	10/29/1999	DAVID E. HECKERMAN	MS131753.03/MSFTP222USB	7721

TITLE OF INVENTION: CLUSTER-BASED AND RULE-BASED APPROACH FOR AUTOMATED WEB-BASED TARGETED ADVERTISING WITH QUOTAS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1440	\$0	\$0	\$1440	12/26/2008

**THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.**

**THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.**

### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

**IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.**





# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/430,767	10/29/1999	DAVID E. HECKERMAN	MS131753.03/MSFTP222USB	7721
27195	7590	09/25/2008	EXAMINER	
AMIN, TUROCY & CALVIN, LLP 24TH FLOOR, NATIONAL CITY CENTER 1900 EAST NINTH STREET CLEVELAND, OH 44114			STARKS, WILBERT L	
			ART UNIT	PAPER NUMBER
			2129	
			DATE MAILED: 09/25/2008	

## Determination of Patent Term Extension under 35 U.S.C. 154 (b)

(application filed after June 7, 1995 but prior to May 29, 2000)

The Patent Term Extension is 0 day(s). Any patent to issue from the above-identified application will include an indication of the 0 day extension on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Extension is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

<b>Notice of Allowability</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/430,767	HECKERMAN ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Wilbert L. Starks, Jr.	2129

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to Applicant's filing of 07/02/2008.

2.  The allowed claim(s) is/are 1,2,4-36,38 and 41-75.

3.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)  All b)  Some\* c)  None of the:

1.  Certified copies of the priority documents have been received.

2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.

3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

5.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.

(a)  including changes required by the Notice of Draftperson's Patent Drawing Review ( PTO-948) attached 1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.

(b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

1. <input type="checkbox"/> Notice of References Cited (PTO-892)	5. <input type="checkbox"/> Notice of Informal Patent Application
2. <input checked="" type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948)	6. <input type="checkbox"/> Interview Summary (PTO-413), Paper No./Mail Date _____.
3. <input type="checkbox"/> Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____.	7. <input type="checkbox"/> Examiner's Amendment/Comment
4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance
	9. <input type="checkbox"/> Other _____.

## DETAILED ACTION

### *Reasons for Allowance*

Claims 1-2, 4-36, 38, and 41-75 are allowed.

The claimed invention is statutory because independent claims 1, 36, 46, 50, 53, 59, 62, 69, 71, and 75 claim the use of "advertisements" which are defined in the Specification, page 23, lines 1-11 as follows:

It is noted that cluster definition gives an a priori look at qualified customers that can then be used when approaching advertisers. That is, the cluster analysis provides a priori the best group of users who would view a predetermined ad. This means that advertisers can then be approached with the information that a web site operator can provide a predetermined reception of ads, without the users having yet actually been exposed to the ads. Thus, the web site operator can determine a price differential to charge different advertisers different advertising rates, based on a priori predetermined reception of users to different advertisers' ads. Each cluster corresponds to a group of users most receptive to a given type of ad. An ad of a particular type is then allocated to the one or more clusters that will provide the ad greatest exposure, or based on some other predetermined criterion.

Further, it is defined in the Specification, page 1, lines 16-25 and page 2, lines 1-3 as follows:

Frequently, advertisers choose sites to pay for banner ad space based on two criteria. First, advertisers pay to have their ads shown to specific types of people. For example, a golf store might want to have its ads shown on a sports-related page, or to people who are likely to be interested in golf based on their browsing history. Second, advertisers pay to have their ads served in such a way that they are likely to be

"clicked on", so that the user will be transported to the advertiser's web site. One way to increase revenue generated from web advertising is thus to increase the "click through" rate of the ads shown; sites with higher click through rates can likely charge more to those advertisers who are interested in attracting people to their web sites. The click through rate of an ad is the percentage of times a user clicks on the ad to be transported to the advertiser's web site, against the number of times the ad is shown. Advertisers in need of advertising are thus attracted to sites that generate click through, and are usually willing to pay extra to those sites that can deliver increased click through.

Therefore the claims, by definition, invoke State Street Bank and are, thereby, statutory.

The following is an Examiner's statement of reasons for allowance: Claims 1-2, 4-36, 38, and 41-75 are considered allowable since when reading the claims in light of the specification, as per MPEP §2111.01, none of the references of record alone or in combination disclose or suggest the combination of limitations specified in independent claim 1, including: an "allocation" (as defined at page 3, lines 1 through 15 and at page 4, lines 10 through 21 and at page 5, lines 16 through 17 and at page 11, lines 15 through 20 and at page 13, lines 20 through 23 and at page 14, lines 5 through 23 and at page 15, lines 5 through 21 and at page 16, lines 1 through 22 and at page 17, lines 1 through 23 and at page 18, lines 1 through 23 and at page 19, lines 1 through 2 and at page 23, lines 9 through 11 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 20), a "selection" (as defined at page 3, line 11 and at page 4, line 8 and at page 11, lines 15 through 21 and at page 14, line 23 and at page 15, line 2 and at page 21, line 13 and at page 25, lines 1 through 23 and at page 26, line 8 and at page 30, lines 1 through 5), an "effecting" (i.e., efferent channel) (as defined at page 5, line 5 and at page 11, lines 19 through 23 and at page 12, line 3

and at page 13, line 19 and at page 28, lines 10 through 15), a "quota" (as defined at page 1, lines 5 through 10 and at page 2, line 13 and at page 3, lines 2 through 20 and at page 4, lines 20 through 23 and at page 11, lines 20 through 23 and at page 13, lines 20 through 23 and at page 14, lines 4 through 20 and at page 15, lines 6 through 10 and at page 15, line 20 and at page 24, lines 1 through 10 and at page 26, lines 5 through 10 and at page 27, lines 5 through 29 and at page 28, lines 1 through 5 and at page 29, lines 1 through 10 and at page 30, lines 10 through 20 and at page 31, lines 1 through 5).

Further, none of the references of record alone or in combination disclose or suggest the combination of limitations specified in independent claim 36, including: an "allocation" (as defined at page 3, lines 1 through 15 and at page 4, lines 10 through 21 and at page 5, lines 16 through 17 and at page 11, lines 15 through 20 and at page 13, lines 20 through 23 and at page 14, lines 5 through 23 and at page 15, lines 5 through 21 and at page 16, lines 1 through 22 and at page 17, lines 1 through 23 and at page 18, lines 1 through 23 and at page 19, lines 1 through 2 and at page 23, lines 9 through 11 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 20), a "monitoring" (as defined at page 4, lines 10 through 20 and at page 9, line 23 and at page 10, lines 1 through 5 and at page 22, lines 15 through 20), a "Bayesian network clustering" algorithm (as defined at page 5, lines 18 through 19 and at page 13, lines 1 through 10 and at page 19, lines 13 through 23 and at page 21, lines 15 through 20 and at page 24, lines 1 through 20), a "cluster" (as defined at page 1, lines 5 through 10 and at page 3, lines 1 through 23 and at page 4, lines 1 through 20

and at page 5, lines 10 through 20 and at page 11, lines 15 through 23 and at page 12, lines 5 through 23 and at page 13, lines 5 through 15 and at page 13, lines 20 through 23 and at page 14, lines 1 through 23 and at page 15, lines 1 through 21 and at page 16, lines 10 through 20 and at page 17, lines 5 through 23 and at page 18, lines 1 through 20 and at page 19, lines 1 through 20 and at page 20, lines 15 through 23 and at page 21, lines 1 through 15 and at page 22, lines 1 through 22 and at page 23, lines 1 through 20 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 15 and at page 29, lines 10 through 15).

Further, none of the references of record alone or in combination disclose or suggest the combination of limitations specified in independent claim 46, including: an "allocation" (as defined at page 3, lines 1 through 15 and at page 4, lines 10 through 21 and at page 5, lines 16 through 17 and at page 11, lines 15 through 20 and at page 13, lines 20 through 23 and at page 14, lines 5 through 23 and at page 15, lines 5 through 21 and at page 16, lines 1 through 22 and at page 17, lines 1 through 23 and at page 18, lines 1 through 23 and at page 19, lines 1 through 2 and at page 23, lines 9 through 11 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 20), a "quota" (as defined at page 1, lines 5 through 10 and at page 2, line 13 and at page 3, lines 2 through 20 and at page 4, lines 20 through 23 and at page 11, lines 20 through 23 and at page 13, lines 20 through 23 and at page 14, lines 4 through 20 and at page 15, lines 6 through 10 and at page 15, line 20 and at page 24, lines 1 through 10 and at page 26, lines 5 through 10 and at page 27, lines 5 through 29 and at page 28, lines 1 through 5 and at page 29, lines 1 through 10 and at page 30,

lines 10 through 20 and at page 31, lines 1 through 5), a "cluster" (as defined at page 1, lines 5 through 10 and at page 3, lines 1 through 23 and at page 4, lines 1 through 20 and at page 5, lines 10 through 20 and at page 11, lines 15 through 23 and at page 12, lines 5 through 23 and at page 13, lines 5 through 15 and at page 13, lines 20 through 23 and at page 14, lines 1 through 23 and at page 15, lines 1 through 21 and at page 16, lines 10 through 20 and at page 17, lines 5 through 23 and at page 18, lines 1 through 20 and at page 19, lines 1 through 20 and at page 20, lines 15 through 23 and at page 21, lines 1 through 15 and at page 22, lines 1 through 22 and at page 23, lines 1 through 20 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 15 and at page 29, lines 10 through 15).

Further, none of the references of record alone or in combination disclose or suggest the combination of limitations specified in independent claim 50, including: an "allocation" (as defined at page 3, lines 1 through 15 and at page 4, lines 10 through 21 and at page 5, lines 16 through 17 and at page 11, lines 15 through 20 and at page 13, lines 20 through 23 and at page 14, lines 5 through 23 and at page 15, lines 5 through 21 and at page 16, lines 1 through 22 and at page 17, lines 1 through 23 and at page 18, lines 1 through 23 and at page 19, lines 1 through 2 and at page 23, lines 9 through 11 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 20), a "quota" (as defined at page 1, lines 5 through 10 and at page 2, line 13 and at page 3, lines 2 through 20 and at page 4, lines 20 through 23 and at page 11, lines 20 through 23 and at page 13, lines 20 through 23 and at page 14, lines 4 through 20 and at page 15, lines 6 through 10 and at page 15, line 20 and at page 24,

lines 1 through 10 and at page 26, lines 5 through 10 and at page 27, lines 5 through 29 and at page 28, lines 1 through 5 and at page 29, lines 1 through 10 and at page 30, lines 10 through 20 and at page 31, lines 1 through 5), a "cluster" (as defined at page 1, lines 5 through 10 and at page 3, lines 1 through 23 and at page 4, lines 1 through 20 and at page 5, lines 10 through 20 and at page 11, lines 15 through 23 and at page 12, lines 5 through 23 and at page 13, lines 5 through 15 and at page 13, lines 20 through 23 and at page 14, lines 1 through 23 and at page 15, lines 1 through 21 and at page 16, lines 10 through 20 and at page 17, lines 5 through 23 and at page 18, lines 1 through 20 and at page 19, lines 1 through 20 and at page 20, lines 15 through 23 and at page 21, lines 1 through 15 and at page 22, lines 1 through 22 and at page 23, lines 1 through 20 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 15 and at page 29, lines 10 through 15).

Further, none of the references of record alone or in combination disclose or suggest the combination of limitations specified in independent claim 53, including: an "allocation" (as defined at page 3, lines 1 through 15 and at page 4, lines 10 through 21 and at page 5, lines 16 through 17 and at page 11, lines 15 through 20 and at page 13, lines 20 through 23 and at page 14, lines 5 through 23 and at page 15, lines 5 through 21 and at page 16, lines 1 through 22 and at page 17, lines 1 through 23 and at page 18, lines 1 through 23 and at page 19, lines 1 through 2 and at page 23, lines 9 through 11 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 20), a "quota" (as defined at page 1, lines 5 through 10 and at page 2, line 13 and at page 3, lines 2 through 20 and at page 4, lines 20 through 23 and at

page 11, lines 20 through 23 and at page 13, lines 20 through 23 and at page 14, lines 4 through 20 and at page 15, lines 6 through 10 and at page 15, line 20 and at page 24, lines 1 through 10 and at page 26, lines 5 through 10 and at page 27, lines 5 through 29 and at page 28, lines 1 through 5 and at page 29, lines 1 through 10 and at page 30, lines 10 through 20 and at page 31, lines 1 through 5), a "selection" (as defined at page 3, line 11 and at page 4, line 8 and at page 11, lines 15 through 21 and at page 14, line 23 and at page 15, line 2 and at page 21, line 13 and at page 25, lines 1 through 23 and at page 26, line 8 and at page 30, lines 1 through 5), a "cluster" (as defined at page 1, lines 5 through 10 and at page 3, lines 1 through 23 and at page 4, lines 1 through 20 and at page 5, lines 10 through 20 and at page 11, lines 15 through 23 and at page 12, lines 5 through 23 and at page 13, lines 5 through 15 and at page 13, lines 20 through 23 and at page 14, lines 1 through 23 and at page 15, lines 1 through 21 and at page 16, lines 10 through 20 and at page 17, lines 5 through 23 and at page 18, lines 1 through 20 and at page 19, lines 1 through 20 and at page 20, lines 15 through 23 and at page 21, lines 1 through 15 and at page 22, lines 1 through 22 and at page 23, lines 1 through 20 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 15 and at page 29, lines 10 through 15).

Further, none of the references of record alone or in combination disclose or suggest the combination of limitations specified in independent claim 59, including: an "allocation" (as defined at page 3, lines 1 through 15 and at page 4, lines 10 through 21 and at page 5, lines 16 through 17 and at page 11, lines 15 through 20 and at page 13, lines 20 through 23 and at page 14, lines 5 through 23 and at page 15, lines 5 through

21 and at page 16, lines 1 through 22 and at page 17, lines 1 through 23 and at page 18, lines 1 through 23 and at page 19, lines 1 through 2 and at page 23, lines 9 through 11 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 20), a "quota" (as defined at page 1, lines 5 through 10 and at page 2, line 13 and at page 3, lines 2 through 20 and at page 4, lines 20 through 23 and at page 11, lines 20 through 23 and at page 13, lines 20 through 23 and at page 14, lines 4 through 20 and at page 15, lines 6 through 10 and at page 15, line 20 and at page 24, lines 1 through 10 and at page 26, lines 5 through 10 and at page 27, lines 5 through 29 and at page 28, lines 1 through 5 and at page 29, lines 1 through 10 and at page 30, lines 10 through 20 and at page 31, lines 1 through 5), a "cluster" (as defined at page 1, lines 5 through 10 and at page 3, lines 1 through 23 and at page 4, lines 1 through 20 and at page 5, lines 10 through 20 and at page 11, lines 15 through 23 and at page 12, lines 5 through 23 and at page 13, lines 5 through 15 and at page 13, lines 20 through 23 and at page 14, lines 1 through 23 and at page 15, lines 1 through 21 and at page 16, lines 10 through 20 and at page 17, lines 5 through 23 and at page 18, lines 1 through 20 and at page 19, lines 1 through 20 and at page 20, lines 15 through 23 and at page 21, lines 1 through 15 and at page 22, lines 1 through 22 and at page 23, lines 1 through 20 and at page 24, lines 1 through 23 and at page 25, lines 1 through 15 and at page 26, lines 1 through 15 and at page 29, lines 10 through 15).

Further, none of the references of record alone or in combination disclose or suggest the combination of limitations specified in independent claim 62, including: an "effecting" (i.e., efferent channel) (as defined at page 5, line 5 and at page 11, lines 19

through 23 and at page 12, line 3 and at page 13, line 19 and at page 28, lines 10 through 15), a "quota" (as defined at page 1, lines 5 through 10 and at page 2, line 13 and at page 3, lines 2 through 20 and at page 4, lines 20 through 23 and at page 11, lines 20 through 23 and at page 13, lines 20 through 23 and at page 14, lines 4 through 20 and at page 15, lines 6 through 10 and at page 15, line 20 and at page 24, lines 1 through 10 and at page 26, lines 5 through 10 and at page 27, lines 5 through 29 and at page 28, lines 1 through 5 and at page 29, lines 1 through 10 and at page 30, lines 10 through 20 and at page 31, lines 1 through 5).

Further, none of the references of record alone or in combination disclose or suggest the combination of limitations specified in independent claim 69, including: a "significant correlation" (as defined at page 29, lines 15 through 20 and at page 30, lines 1 through 5 and at page 30, lines 20 through 22 and at page 31, lines 1 through 5), an "activation" (as defined at page 28, lines 1 through 10 and at page 29, lines 15 through 20 and at page 30, lines 5 through 10 and at page 31, lines 15 through 20), a set of "training data" (as defined at page 13, lines 5 through 15 and at page 24, lines 10 through 15 and at page 28, lines 15 through 20 and at page 29, lines 5 through 10), a "quota" (as defined at page 1, lines 5 through 10 and at page 2, line 13 and at page 3, lines 2 through 20 and at page 4, lines 20 through 23 and at page 11, lines 20 through 23 and at page 13, lines 20 through 23 and at page 14, lines 4 through 20 and at page 15, lines 6 through 10 and at page 15, line 20 and at page 24, lines 1 through 10 and at page 26, lines 5 through 10 and at page 27, lines 5 through 29 and at page 28, lines 1

through 5 and at page 29, lines 1 through 10 and at page 30, lines 10 through 20 and at page 31, lines 1 through 5).

Further, none of the references of record alone or in combination disclose or suggest the combination of limitations specified in independent claim 71, including: an "effecting" (i.e., efferent channel) (as defined at page 5, line 5 and at page 11, lines 19 through 23 and at page 12, line 3 and at page 13, line 19 and at page 28, lines 10 through 15), a "quota" (as defined at page 1, lines 5 through 10 and at page 2, line 13 and at page 3, lines 2 through 20 and at page 4, lines 20 through 23 and at page 11, lines 20 through 23 and at page 13, lines 20 through 23 and at page 14, lines 4 through 20 and at page 15, lines 6 through 10 and at page 15, line 20 and at page 24, lines 1 through 10 and at page 26, lines 5 through 10 and at page 27, lines 5 through 29 and at page 28, lines 1 through 5 and at page 29, lines 1 through 10 and at page 30, lines 10 through 20 and at page 31, lines 1 through 5).

Further, none of the references of record alone or in combination disclose or suggest the combination of limitations specified in independent claim 75, including: a "significant correlation" (as defined at page 29, lines 15 through 20 and at page 30, lines 1 through 5 and at page 30, lines 20 through 22 and at page 31, lines 1 through 5), an "activation" (as defined at page 28, lines 1 through 10 and at page 29, lines 15 through 20 and at page 30, lines 5 through 10 and at page 31, lines 15 through 20), a set of "training data" (as defined at page 13, lines 5 through 15 and at page 24, lines 10 through 15 and at page 28, lines 15 through 20 and at page 29, lines 5 through 10), a "quota" (as defined at page 1, lines 5 through 10 and at page 2, line 13 and at page 3,

lines 2 through 20 and at page 4, lines 20 through 23 and at page 11, lines 20 through 23 and at page 13, lines 20 through 23 and at page 14, lines 4 through 20 and at page 15, lines 6 through 10 and at page 15, line 20 and at page 24, lines 1 through 10 and at page 26, lines 5 through 10 and at page 27, lines 5 through 29 and at page 28, lines 1 through 5 and at page 29, lines 1 through 10 and at page 30, lines 10 through 20 and at page 31, lines 1 through 5).

Only to the extent that these features are not found in the prior art of record is the present case allowable over the prior art.

***Conclusion***

Any comments considered necessary by Applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Wilbert L. Starks, Jr. whose telephone number is (571) 272-3691.

Alternatively, inquiries may be directed to the following:

**S. P. E. David Vincent** (571) 272-3080  
**Official (FAX)** (571) 273-8300

/Wilbert L. Starks, Jr./

Primary Examiner, Art Unit 2129

WLS

01 SEP 2008